Moderna, Inc. - Common Stock (MRNA)
228.44
+7.61 (3.45%)
NASDAQ · Last Trade: Nov 3rd, 11:16 PM EST
News & Press Releases
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Successfool.com
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Via The Motley Fool · November 3, 2026
Tempus AI Surges on Earnings Beat, But Can the Rally Last?marketbeat.com
Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.
Via MarketBeat · November 3, 2026
Could Investing in Moderna's Stock Double Your Money?fool.com
The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future.
Via The Motley Fool · November 3, 2026
If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Startedfool.com
Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma.
Via The Motley Fool · November 2, 2026
Stock Split Watch: Is Moderna Next?fool.com
Moderna stock has skyrocketed this year.
Via The Motley Fool · November 2, 2026
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay Awayfool.com
These biotechs’ valuations are through the roof.
Via The Motley Fool · October 29, 2026
Will Moderna Soar on Nov. 6?fool.com
Moderna shares have outperformed tech giants this year.
Via The Motley Fool · October 29, 2026
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatilityfool.com
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
Via The Motley Fool · October 28, 2026
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?marketbeat.com
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Via MarketBeat · October 27, 2026
S&P 500 Premarket Movers: Royal Caribbean, S&P Global Gain; Xylem, Sherwin-Williams Fallchartmill.com
Via Chartmill · October 27, 2026
S&P 500 Gap-Down Stocks for Oct. 26, 2026chartmill.com
Via Chartmill · October 26, 2026
S&P 500 Premarket Movers: Gainers and Losers Before the Openchartmill.com
Via Chartmill · October 26, 2026
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.
By Biotech Insider · Via GlobeNewswire · October 26, 2026
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END
Via FinancialNewsMedia · October 26, 2026
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trialmarketbeat.com
Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di
Via MarketBeat · October 24, 2026
Most Active S&P 500 Stocks for Oct. 23, 2026chartmill.com
Via Chartmill · October 23, 2026
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?fool.com
The stock fell 17% in one trading session.
Via The Motley Fool · October 23, 2026
Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop
Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · October 23, 2026
Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 23.07% Share Price Decline
Investors who suffered losses on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 22, 2026 disclosure concerning Moderna, Inc.
By Law Offices of Howard G. Smith · Via Business Wire · October 23, 2026
S&P 500 Premarket Movers: CCI and SBAC Lead Gainers, TYL and DECK Top Declinerschartmill.com
Via Chartmill · October 23, 2026
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.
By Moderna, Inc. · Via ACCESS Newswire · October 23, 2026
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reportsfool.com
Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.
Via The Motley Fool · October 22, 2026
Why Moderna (MRNA) stock is trading lower today
What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its per...
Via StockStory · October 22, 2026
Lost Money on Moderna, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 23.07% Stock Decline
Moderna, Inc. ("Moderna" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Moderna, Inc. (NASDAQ: MRNA), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Moderna, Inc. on October 22, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · October 22, 2026
S&P 500 Top Movers: Gainers and Losers for Oct. 22, 2026chartmill.com
Via Chartmill · October 22, 2026